PacBio (PACB) To Report Earnings Tomorrow: Here Is What To Expect
Pacific Biosciences of California (NASDAQ: PACB) will report earnings Wednesday afternoon. Last quarter it reported revenue of $37.18 million, flat year over year, missing analysts’ revenue expectations, while EPS beat. This quarter, analysts expect revenue to be flat. The article cites an average analyst price target of $2.46 versus $1.43.
How this was made
The 30-second read
Why it matters
Traders should focus on whether reported revenue matches the flat YoY expectation and whether EPS strength offsets any revenue softness, since consensus estimates were largely reconfirmed over the last 30 days.
Market read
This is a pre-earnings setup for PACB with specific prior-quarter context and consensus framing, but without new guidance or a fresh earnings datapoint yet.
What to watch
The article does not discuss guidance, margins, cash flow, or backlog, which are often the real drivers of post-earnings repricing for genomics tools companies.
Background
PacBio missed analysts’ revenue expectations last quarter and has missed revenue estimates multiple times over the last two years.
Ticker impact
PacBio (PACB) is scheduled to report earnings Wednesday afternoon, after missing prior-quarter revenue expectations and facing flat YoY revenue expectations.
Likely volatility around revenue and EPS versus reconfirmed consensus, with downside risk if revenue remains flat or misses again.
The article provides timing (Wednesday afternoon) and recent performance context (repeated revenue misses), but does not include new guidance or a fresh datapoint beyond expectations.
Market effects
Peers in life sciences tools showed mixed-to-positive results, which may set a read-across for investor expectations around demand and execution.
No specific regional impact described.
No explicit global macro or cross-border catalyst described.
Counterpoint
Even with flat YoY revenue expectations, the stock could react positively if EPS beats are sustained and management signals improving commercial momentum.
Key entities
- companyPacBio
Genomics company scheduled to report earnings Wednesday afternoon; recently missed revenue expectations and is down 14% over the last month.
- peerIllumina
Reported year-on-year revenue growth of 9.4% and was unchanged after results, used as a read-across in the article.
- peerUFP Technologies
Reported revenues up 15.1% and topped estimates by 9.1%, also used as a read-across.
